Quest Diagnostics (DGX) Boosts Oncology Portfolio With New Test

Quest Diagnostics (DGX) recently introduced a highly advanced predictive gene expression test, MelaNodal Predict, to help personalize treatment decisions for patients with melanoma.  The lab-developed test is based on the technology developed by the biotechnology company, SkylineDx, alongside Mayo Clinic and has been validated by DGX.The latest development will strongly fortify the company’s oncology test offering across the advanced diagnostics spectrum. Dermatologists and other providers nationwide can be ...